H.C. Wainwright initiated coverage of HeartBeam (BEAT) with a Buy rating and $2.50 price target The firm says HeartBeam is a clinical-stage medical device company focused on the development of a portable cable-free device capable of collecting electrocardiogram signals from three non-coplanar dimensions and synthesizing the signals into a 12-lead ECG.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAT:
- HeartBeam (NASDAQ: BEAT) Outlines Regulatory Strategy After NSE Decision on ECG Synthesis Software
- HeartBeam’s Strategic Path to Overcome Regulatory Challenges and Secure Buy Rating
- HeartBeam updates regulatory strategy for 12-lead ECG Synthesis Software
- Roth sees potential FDA clearance for HeartBeam despite letter
- HeartBeam sinks after ‘Not Substantially Equivalent’ letter from FDA